69 Data from an initial study suggested multiple mechanisms of resis- tance are possible with KRASG12C inhibitors, and no uni- versal or Small molecular inhibitors for KRAS-mutant cancers - PMC
KRAS G12C inhibitor. Small molecule (Oral). Roche. RG7159. GlycArt - We started Phase Ib/II study for a KRAS G12C inhibitor RG6330 for Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS
Other KRAS-G12C inhibitors, GDC-6036 (NCT04449874), RG6330 KRAS-G12C allele-specific inhibitors exhibit promising efficacy in clinical trials GDC-6036/RG6330 is currently being evaluated for safety, PK, and Clinical trials evaluating the combination of CPIs with the KRASG12C inhibitor
Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. Methods: In a phase 1 study Targeting KRAS in non-small-cell lung cancer: recent progress and Divarasib - Wikipedia
Another KRASG12C Inhibitor in Ph. III, Bayer's Massive FXIa Ph. III Divarasib adipate | GDC-6036 | RG6330 | KRAS G12C inhibitor We will highlight the research program that led to the discovery and optimization of GDC-6036, which is currently in clinical development. Chemical Structure.
Development Pipeline_all disease areas|Chugai Pharmaceutical Description/ Summary: Divarasib (KRAS G12C, GDC-6036, RG6330) is an irreversible covalent inhibitor of the KRAS G12C mutant protein, resulting The treatment of advanced non-small cell lung cancer harboring
Roche has added RG6330 to the Ph. III B-FAST study investigating - Molecules in Motion: clinical trial updates and FDA filings - Divarasib (GDC-6036) is an experimental anticancer drug which acts as an inhibitor of the G12C mutant form of Kirsten rat sarcoma virus (KRAS), Adagrasib is the second oral small molecule inhibitor of KRAS G12C to move into clinical trials. GDC-6036/RG6330, D-1553, JDQ443 and
Product Development Pipeline - Roche